However, severe toxicities were reported after use of checkpoint blockade inhibitors, including 23% grade 3 or 4 adverse effects, such as inflammatory colitis and hypophysitis after use of anti-CTLA4 antibodies and cardiomyopathy and lung infiltrations after application of anti-PD-L1/PD-1 antibodies [38,43]. This evidence concerns the gene CTLA4 and cardiomyopathy.